Beyond generics: Glenmark resets agenda with a bold 10-year pivot to global drug innovation, says chairman Saldanha
For chairman Glenn Saldanha, the way forward is a mix of licensing deals, partnerships and Glenmark’s own commercialization in emerging markets.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)